QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.01
(-16.77%)
SEK 0.01
(-16.77%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 20.51 Million SEK | 58.31% |
| 2022 | 12.95 Million SEK | 4.0% |
| 2021 | 12.45 Million SEK | 73.95% |
| 2020 | 7.16 Million SEK | -43.91% |
| 2019 | 12.76 Million SEK | 302.43% |
| 2018 | 3.17 Million SEK | 974.1% |
| 2017 | -363 Thousand SEK | 97.98% |
| 2016 | -17.99 Million SEK | -430.13% |
| 2015 | -3.39 Million SEK | -20.05% |
| 2014 | -2.82 Million SEK | -37.21% |
| 2013 | -2.06 Million SEK | -135.01% |
| 2012 | -877 Thousand SEK | 83.91% |
| 2011 | -5.45 Million SEK | -4.73% |
| 2010 | -5.2 Million SEK | -58.64% |
| 2009 | -3.28 Million SEK | -90.87% |
| 2008 | -1.71 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 748 Thousand SEK | 0.0% |
| 2024 Q1 | 748 Thousand SEK | -96.35% |
| 2023 Q1 | 8.28 Million SEK | -36.05% |
| 2023 Q2 | 8.28 Million SEK | 0.0% |
| 2023 Q3 | 20.51 Million SEK | 147.53% |
| 2023 Q4 | 20.51 Million SEK | 0.0% |
| 2023 FY | 20.51 Million SEK | 58.31% |
| 2022 Q4 | 12.95 Million SEK | 59.44% |
| 2022 FY | 12.95 Million SEK | 4.0% |
| 2022 Q1 | 19.74 Million SEK | 58.5% |
| 2022 Q2 | 3.4 Million SEK | -82.76% |
| 2022 Q3 | 8.12 Million SEK | 138.65% |
| 2021 Q4 | 12.45 Million SEK | 18.16% |
| 2021 Q3 | 10.54 Million SEK | 771.96% |
| 2021 Q2 | -1.56 Million SEK | -131.63% |
| 2021 Q1 | 4.96 Million SEK | -30.75% |
| 2021 FY | 12.45 Million SEK | 73.95% |
| 2020 Q4 | 7.16 Million SEK | 247.43% |
| 2020 Q2 | 21.76 Million SEK | 96.39% |
| 2020 Q3 | -4.85 Million SEK | -122.32% |
| 2020 Q1 | 11.08 Million SEK | -13.2% |
| 2020 FY | 7.16 Million SEK | -43.91% |
| 2019 Q2 | -367 Thousand SEK | 92.91% |
| 2019 Q4 | 12.76 Million SEK | 296.92% |
| 2019 FY | 12.76 Million SEK | 302.43% |
| 2019 Q1 | -5.17 Million SEK | -263.13% |
| 2019 Q3 | 3.21 Million SEK | 976.57% |
| 2018 Q3 | -3.15 Million SEK | 55.71% |
| 2018 FY | 3.17 Million SEK | 974.1% |
| 2018 Q4 | 3.17 Million SEK | 200.54% |
| 2018 Q2 | -7.12 Million SEK | -514.84% |
| 2018 Q1 | -1.15 Million SEK | -219.28% |
| 2017 FY | -363 Thousand SEK | 97.98% |
| 2017 Q1 | -20.15 Million SEK | -12.0% |
| 2017 Q2 | -6.72 Million SEK | 66.63% |
| 2017 Q3 | -7.68 Million SEK | -14.26% |
| 2017 Q4 | -363 Thousand SEK | 95.28% |
| 2016 Q1 | -3.12 Million SEK | 7.89% |
| 2016 FY | -17.99 Million SEK | -430.13% |
| 2016 Q2 | -1.59 Million SEK | 48.96% |
| 2016 Q3 | -4.4 Million SEK | -176.13% |
| 2016 Q4 | -17.99 Million SEK | -308.4% |
| 2015 Q4 | -3.39 Million SEK | 0.0% |
| 2015 FY | -3.39 Million SEK | -20.05% |
| 2015 Q2 | -2.76 Million SEK | 0.0% |
| 2014 FY | -2.82 Million SEK | -37.21% |
| 2014 Q4 | -2.82 Million SEK | 0.0% |
| 2014 Q2 | -1.22 Million SEK | 0.0% |
| 2013 FY | -2.06 Million SEK | -135.01% |
| 2013 Q2 | -304 Thousand SEK | 0.0% |
| 2013 Q4 | -2.06 Million SEK | 0.0% |
| 2012 FY | -877 Thousand SEK | 83.91% |
| 2012 Q4 | -877 Thousand SEK | 0.0% |
| 2012 Q2 | -4.29 Million SEK | 0.0% |
| 2011 Q2 | -6.02 Million SEK | 0.0% |
| 2011 FY | -5.45 Million SEK | -4.73% |
| 2010 Q2 | -3.04 Million SEK | 0.0% |
| 2010 FY | -5.2 Million SEK | -58.64% |
| 2009 FY | -3.28 Million SEK | -90.87% |
| 2008 FY | -1.71 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | 196.627% |
| Amniotics AB (publ) | -5.63 Million SEK | 464.169% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 1049.098% |
| BioArctic AB (publ) | -606.58 Million SEK | 103.381% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | -279.815% |
| Saniona AB (publ) | 40.44 Million SEK | 49.292% |
| Simris Alg AB (publ) | 85.07 Million SEK | 75.892% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 106.148% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 2322.102% |
| NextCell Pharma AB | -46.79 Million SEK | 143.834% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 169.802% |
| AcouSort AB (publ) | -23.98 Million SEK | 185.508% |
| Active Biotech AB (publ) | -33.2 Million SEK | 161.777% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 141.003% |
| Camurus AB (publ) | -1.16 Billion SEK | 101.76% |
| Cantargia AB (publ) | -139.74 Million SEK | 114.677% |
| Genovis AB (publ.) | -43.94 Million SEK | 146.676% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 124.492% |
| Mendus AB (publ) | -96.29 Million SEK | 121.299% |
| Kancera AB (publ) | -45.69 Million SEK | 144.888% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 124.951% |
| LIDDS AB (publ) | -13.51 Million SEK | 251.791% |
| Lipum AB (publ) | -8.46 Million SEK | 342.292% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 164.24% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 61.464% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 207.608% |
| OncoZenge AB (publ) | -12.62 Million SEK | 262.43% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 87.65% |
| Xintela AB (publ) | -7.8 Million SEK | 362.646% |
| Ziccum AB (publ) | -2.13 Million SEK | 1059.757% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 114.846% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 115.838% |
| CombiGene AB (publ) | -101.44 Million SEK | 120.219% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 124.986% |
| Intervacc AB (publ) | -88.16 Million SEK | 123.265% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 141.074% |
| Corline Biomedical AB | -17.01 Million SEK | 220.562% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 124.492% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 152.08% |
| Aptahem AB (publ) | 2.9 Million SEK | -605.14% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 106.233% |
| Fluicell AB (publ) | -2.76 Million SEK | 842.309% |
| Biovica International AB (publ) | -58.73 Million SEK | 134.918% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 145.359% |
| Abliva AB (publ) | -57.24 Million SEK | 135.832% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 110.534% |
| 2cureX AB (publ) | -13.4 Million SEK | 253.025% |
| I-Tech AB | -83.26 Million SEK | 124.633% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 84.774% |
| Cyxone AB (publ) | -16.67 Million SEK | 223.035% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 136.7% |
| Biosergen AB | -1.88 Million SEK | 1189.219% |
| Nanologica AB (publ) | -9.38 Million SEK | 318.47% |
| SynAct Pharma AB | -61.75 Million SEK | 133.21% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 195.774% |
| BioInvent International AB (publ) | -236.3 Million SEK | 108.679% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 255.036% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 130.649% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 495.876% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 198.639% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 790.108% |